CoChat
Sign Up
Cited by 948

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential

Song, Na, Scholtemeijer, Martijn, Shah, Khalid·2020·Trends in Pharmacological Sciences
DOI 10.1016/j.tips.2020.06.009PMC PMC7751844
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tips.2020.06.009

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 93

  1. Galipeau, 2018, Mesenchymal stromal cells: clinical challenges and therapeutic opportunities, Cell Stem Cell, 22, 824, 10.1016/j.stem.2018.05.004 · DOI · Paper page
  2. Timaner, 2019, The multifaceted role of mesenchymal stem cells in cancer, Semin. Cancer Biol., 60, 225, 10.1016/j.semcancer.2019.06.003 · DOI
  3. Chen, 2008, Mesenchymal stem cells: a promising candidate in regenerative medicine, Intl. J. Biochem. Cell Biol., 40, 815, 10.1016/j.biocel.2008.01.007 · DOI
  4. Shah, 2012, Mesenchymal stem cells engineered for cancer therapy, Adv. Drug Deliv. Rev., 64, 739, 10.1016/j.addr.2011.06.010 · DOI
  5. Heo, 2016, Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue, Intl. J. Molec. Med., 37, 115, 10.3892/ijmm.2015.2413 · DOI · Paper page
  6. Kim, 2018, Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue, Stem Cells Int., 2018, 8429042, 10.1155/2018/8429042 · DOI
  7. Shah, 2016, Stem cell-based therapies for tumors in the brain: are we there yet?, Neuro-oncology, 18, 1066, 10.1093/neuonc/now096 · DOI
  8. Weiss, 2019, Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs, Front. Immunol., 10, 1191, 10.3389/fimmu.2019.01191 · DOI
  9. Melief, 2013, Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6, Haematologica, 98, 888, 10.3324/haematol.2012.078055 · DOI
  10. Krampera, 2003, Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, Blood, 101, 3722, 10.1182/blood-2002-07-2104 · DOI
  11. Ren, 2010, Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression, J. Immunol., 184, 2321, 10.4049/jimmunol.0902023 · DOI
  12. Najar, 2019, Immunological modulation following bone marrow-derived mesenchymal stromal cells and Th17 lymphocyte co-cultures, Inflamm. Res., 68, 203, 10.1007/s00011-018-1205-0 · DOI
  13. Del Papa, 2013, Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction, Eur. J. Immunol., 43, 182, 10.1002/eji.201242643 · DOI
  14. Gieseke, 2010, Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells, Blood, 116, 3770, 10.1182/blood-2010-02-270777 · DOI
  15. Liotta, 2008, Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling, Stem Cells, 26, 279, 10.1634/stemcells.2007-0454 · DOI
  16. Wang, 2013, Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells, Cell Biol. Int., 37, 137, 10.1002/cbin.10024 · DOI
  17. Zeng, 2019, CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer, Oncotarget, 10, 4472, 10.18632/oncotarget.27065 · DOI
  18. Li, 2019, Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models, Cell. Mol. Immunol., 16, 908, 10.1038/s41423-019-0204-6 · DOI
  19. Sheng, 2008, A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1, Cell Res., 18, 846, 10.1038/cr.2008.80 · DOI
  20. Franquesa, 2015, Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells, Stem Cells, 33, 880, 10.1002/stem.1881 · DOI
  21. Healy, 2015, Mesenchymal stromal cells protect against caspase 3-mediated apoptosis of CD19+ peripheral B cells through contact-dependent upregulation of VEGF, Stem Cells Dev., 24, 2391, 10.1089/scd.2015.0089 · DOI
  22. Tabera, 2008, The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes, Haematologica, 93, 1301, 10.3324/haematol.12857 · DOI · Paper page
  23. de Witte, 2018, Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells, Stem Cells, 36, 602, 10.1002/stem.2779 · DOI · Paper page
  24. Hu, 2019, Differential immunomodulatory effects of human bone marrow-derived mesenchymal stromal cells on natural killer cells, Stem Cells Dev., 28, 933, 10.1089/scd.2019.0059 · DOI
  25. Manferdini, 2017, Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation, Osteoarthr. Cartil., 25, 1161, 10.1016/j.joca.2017.01.011 · DOI
  26. Jiang, 2016, Suppression of neutrophil-mediated tissue damage – a novel skill of mesenchymal stem cells, Stem Cells, 34, 2393, 10.1002/stem.2417 · DOI · Paper page
  27. Li, 2017, Interactions between mesenchymal stem cells and the immune system, Cell. Mol. Life Sci., 74, 2345, 10.1007/s00018-017-2473-5 · DOI · Paper page
  28. Salgado, 2010, Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine, Curr. Stem Cell Res. Ther., 5, 103, 10.2174/157488810791268564 · DOI
  29. Ferreira, 2018, Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning, Front. Immunol., 9, 2832, 10.3389/fimmu.2018.02837 · DOI · Paper page
  30. Mardpour, 2019, Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content, J. Cell. Physiol., 234, 8249, 10.1002/jcp.27669 · DOI
  31. Madrigal, 2014, A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods, J. Transl. Med., 12, 262, 10.1186/s12967-014-0260-8 · DOI
  32. Ghannam, 2010, Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype, J. Immunol., 185, 302, 10.4049/jimmunol.0902007 · DOI
  33. Wang, 2015, Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses, Stem Cell Reports, 5, 392, 10.1016/j.stemcr.2015.07.013 · DOI
  34. Ge, 2010, Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression, Transplantation, 90, 1312, 10.1097/TP.0b013e3181fed001 · DOI
  35. Wen, 2016, Mesenchymal stem cell and derived exosome as small RNA carrier and Immunomodulator to improve islet transplantation, J. Control. Release, 238, 166, 10.1016/j.jconrel.2016.07.044 · DOI
  36. Davies, 2017, Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression, Stem Cells, 35, 766, 10.1002/stem.2509 · DOI
  37. Spaggiari, 2006, Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation, Blood, 107, 1484, 10.1182/blood-2005-07-2775 · DOI
  38. Spaggiari, 2008, Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2, Blood, 111, 1327, 10.1182/blood-2007-02-074997 · DOI
  39. Thomas, 2014, Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion, Mediat. Inflamm., 2014, 143463, 10.1155/2014/143463 · DOI
  40. Raffaghello, 2008, Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche, Stem Cells, 26, 151, 10.1634/stemcells.2007-0416 · DOI
  41. Mahmoudi, 2019, Comparison of the effects of adipose tissue mesenchymal stromal cell-derived exosomes with conditioned media on neutrophil function and apoptosis, Int. Immunopharmacol., 74, 105682, 10.1016/j.intimp.2019.105689 · DOI
  42. Brandau, 2014, Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes, PLoS One, 9, 10.1371/journal.pone.0106903 · DOI
  43. Melief, 2013, Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts, Stem Cells Transl. Med., 2, 455, 10.5966/sctm.2012-0184 · DOI · Paper page
  44. Spaggiari, 2009, MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2, Blood, 113, 6576, 10.1182/blood-2009-02-203943 · DOI
  45. Sicco, 2017, Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization, Stem Cells Transl. Med., 6, 1018, 10.1002/sctm.16-0363 · DOI
  46. Abumaree, 2013, Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages, Stem Cell Rev. Rep., 9, 620, 10.1007/s12015-013-9455-2 · DOI
  47. Silva, 2018, Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases, Stem Cell Res Ther, 9, 42, 10.1186/s13287-018-0802-8 · DOI
  48. Zhang, 2014, Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities, Biomed. Res. Int., 2014, 462
  49. Lan, 2015, Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis, Stem Cell Res Ther, 6, 92, 10.1186/s13287-015-0081-6 · DOI
  50. Martinez, 2017, Overexpression of hypoxia-inducible factor 1 alpha improves immunomodulation by dental mesenchymal stem cells, Stem Cell Res Ther, 8, 202, 10.1186/s13287-017-0659-2 · DOI
  51. Sivanathan, 2017, Immunodepletion and hypoxia preconditioning of mouse compact bone cells as a novel protocol to isolate highly immunosuppressive mesenchymal stem cells, Stem Cells Dev., 26, 512, 10.1089/scd.2016.0180 · DOI
  52. Fierro, 2015, Hypoxic pre-conditioning increases the infiltration of endothelial cells into scaffolds for dermal regeneration pre-seeded with mesenchymal stem cells, Front. Cell Dev. Biol., 3, 62, 10.3389/fcell.2015.00068 · DOI
  53. Elabd, 2018, Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome: implication for stem cell therapies targeting intervertebral discs, J. Transl. Med., 16, 222, 10.1186/s12967-018-1601-9 · DOI
  54. Kadle, 2018, Microenvironmental cues enhance mesenchymal stem cell-mediated immunomodulation and regulatory T-cell expansion, PLoS One, 13, 10.1371/journal.pone.0193178 · DOI
  55. Kim, 2018, Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease, Leukemia, 32, 2672, 10.1038/s41375-018-0151-8 · DOI
  56. Boland, 2018, IFN-γ and TNF-α pre-licensing protects mesenchymal stromal cells from the pro-inflammatory effects of palmitate, Mol. Ther., 26, 860, 10.1016/j.ymthe.2017.12.013 · DOI
  57. Zimmermann, 2017, Enhanced immunosuppression of T cells by sustained presentation of bioactive interferon-γ within three-dimensional mesenchymal stem cell constructs, Stem Cells Transl. Med., 6, 223, 10.5966/sctm.2016-0044 · DOI
  58. Klinker, 2017, Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity, Proc. Natl. Acad. Sci., 114, E2598, 10.1073/pnas.1617933114 · DOI
  59. Kim, 2018, Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ, EBioMedicine, 28, 261, 10.1016/j.ebiom.2018.01.002 · DOI
  60. da Costa Gonçalves, 2017, Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes, Sci. Rep., 7, 12100, 10.1038/s41598-017-12121-z · DOI
  61. Bolhassani, 2019, Modified DCs and MSCs with HPV E7 antigen and small Hsps: which one is the most potent strategy for eradication of tumors?, Mol. Immunol., 108, 102, 10.1016/j.molimm.2019.02.016 · DOI
  62. Choi, 2017, Tumor resection recruits effector T cells and boosts therapeutic efficacy of encapsulated stem cells expressing IFNβ in glioblastomas, Clin. Cancer Res., 23, 7047, 10.1158/1078-0432.CCR-17-0077 · DOI
  63. Relation, 2018, Intratumoral delivery of interferonγ-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo, Stem Cells, 36, 915, 10.1002/stem.2801 · DOI
  64. Song, 2020, Interleukin-4 gene transfection and spheroid formation potentiate therapeutic efficacy of mesenchymal stem cells for osteoarthritis, Adv. Healthc. Mater., 9, 10.1002/adhm.201901612 · DOI
  65. Gao, 2010, Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma, Cancer Lett., 290, 157, 10.1016/j.canlet.2009.08.031 · DOI
  66. Jing, 2014, Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice, Mol. Cancer Ther., 13, 2127, 10.1158/1535-7163.MCT-14-0175 · DOI
  67. Kim, 2015, IL-21-expressing mesenchymal stem cells prevent lethal B-cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor, Stem Cells Dev., 24, 2808, 10.1089/scd.2015.0103 · DOI
  68. Jeon, 2018, Engineered mesenchymal stem cells expressing stromal cell-derived factor-1 improve erectile dysfunction in streptozotocin-induced diabetic rats, Int. J. Mol. Sci., 19, 3732, 10.3390/ijms19123730 · DOI
  69. Lou, 2020, MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway, J. Exp. Clin. Cancer Res., 39, 4, 10.1186/s13046-019-1512-5 · DOI
  70. Kavari, 2020, Engineered stem cells targeting multiple cell surface receptors in tumors, Stem Cells, 38, 34, 10.1002/stem.3069 · DOI
  71. Du, 2017, Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas, Proc. Natl. Acad. Sci., 114, E6157, 10.1073/pnas.1700363114 · DOI
  72. Yoon, 2019, Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma, Cancer Res., 79, 4503, 10.1158/0008-5472.CAN-18-3900 · DOI
  73. Moreno, 2019, Enhanced antitumor efficacy of oncolytic adenovirus-loaded menstrual blood-derived mesenchymal stem cells in combination with peripheral blood mononuclear cells, Mol. Cancer Ther., 18, 127, 10.1158/1535-7163.MCT-18-0431 · DOI
  74. Kaczorowski, 2016, Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells, Oncotarget, 7, 9042, 10.18632/oncotarget.7031 · DOI
  75. Niess, 2015, Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial, BMC Cancer, 15, 232, 10.1186/s12885-015-1241-x · DOI
  76. von Einem, 2019, Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the phase 1/2 TREAT-ME-1 trial, Int. J. Cancer, 145, 1538, 10.1002/ijc.32230 · DOI
  77. Chahal, 2019, Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation, Stem Cells Transl. Med., 8, 746, 10.1002/sctm.18-0183 · DOI
  78. Muroi, 2016, Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study, Int. J. Hematol., 103, 243, 10.1007/s12185-015-1915-9 · DOI
  79. Connick, 2012, Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study, Lancet Neurol., 11, 150, 10.1016/S1474-4422(11)70305-2 · DOI
  80. Kim, 2017, Clinical trial of human umbilical cord blood-derived stem cells for the treatment of moderate-to-severe atopic dermatitis: Phase I/IIa studies, Stem Cells, 35, 248, 10.1002/stem.2401 · DOI
  81. Ciccocioppo, 2011, Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease, Gut, 60, 788, 10.1136/gut.2010.214841 · DOI
  82. Panés, 2016, Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial, Lancet, 388, 1281, 10.1016/S0140-6736(16)31203-X · DOI
  83. Herz, 2018, Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury, Brain Behav. Immun., 70, 118, 10.1016/j.bbi.2018.02.006 · DOI
  84. Popielarczyk, 2019, Human bone marrow-derived mesenchymal stem cells home via the PI3K-Akt, MAPK, and Jak/Stat signaling pathways in response to platelet-derived growth factor, Stem Cells Dev., 28, 1191, 10.1089/scd.2019.0003 · DOI
  85. Shahror, 2019, Enhanced homing of mesenchymal stem cells overexpressing fibroblast growth factor 21 to injury site in a mouse model of traumatic brain injury, Int. J. Mol. Sci., 20, 2622, 10.3390/ijms20112624 · DOI
  86. Park, 2019, A novel endogenous damage signal, CSF-2, activates multiple beneficial functions of adipose tissue-derived mesenchymal stem cells, Mol. Ther., 27, 1087, 10.1016/j.ymthe.2019.03.010 · DOI
  87. Chen, 2018, IL-1β-Induced matrix metalloprotease-1 promotes mesenchymal stem cell migration via PAR1 and G-protein-coupled signaling pathway, Stem Cells Int., 2018, 3524759, 10.1155/2018/3524759 · DOI
  88. Meng, 2018, LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning, Stem Cell Res. Ther., 9, 280, 10.1186/s13287-018-1031-x · DOI
  89. Oja, 2019, The utilization of freezing steps in mesenchymal stromal cell (MSC) manufacturing: potential impact on quality and cell functionality attributes, Front. Immunol., 10, 1622, 10.3389/fimmu.2019.01627 · DOI
  90. Zhu, 2017, Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors, Sci. Rep., 7, 2602, 10.1038/s41598-017-02483-9 · DOI
  91. Zhang, 2017, Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan, J. Hematol. Oncol., 10, 52, 10.1186/s13045-017-0397-z · DOI · Paper page
  92. Liu, 2006, The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells, J. Immunol., 176, 2864, 10.4049/jimmunol.176.5.2864 · DOI
  93. Isakova, 2014, Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo, PLoS One, 9, 10.1371/journal.pone.0087238 · DOI

Cited by

Sorted by citations

See all 948

Metadata

Authors
Song, N., Scholtemeijer, M., & Shah, K.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2020-09
Volume
41
Issue
9
Pages
653-664
ISSN
0165-6147
DOI
10.1016/j.tips.2020.06.009
PMC
PMC7751844
Cited by
948
References
9
Language
en
Licence
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. https://app.cochat.ai/papers/10.1016/j.tips.2020.06.009
The paper
Song, N., Scholtemeijer, M., & Shah, K. (2020). Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2020.06.009